KiTZ Clinical Trial Unit (ZIPO)
+49 6221 5637082
zipo.ambulanz(at)med.uni-heidelberg.de
Head: Prof. Dr. med. Olaf Witt
Deputy head: Prof. Dr. med. Stefan Pfister
Im Neuenheimer Feld 430
D-69120 Heidelberg
Innovative Phase I/II Studies
Once children and adolescents suffer a disease relapse, despite first-line therapy and intensive pre-treatment, their chances of recovery are often limited ̶ especially in the case of solid tumors or brain tumors. Thanks to far-reaching developments in molecular genetic analysis and a large number of new so-called targeted drugs and immunotherapeutic approaches, we are confident to better help these children in the near future.
Current studies on individualized therapies
- Pan-RAF-Inhibitors DAY101 bei BRAF-veränderten, rezidivierenden oder progredienten LGGs (FIREFLY-1)
- INFORM2-NivEnt for children and adolescents with high-risk refractory cancers
- TRK-inhibitor Larotrectinib in children with advanced solid or primary tumors of the central nervous system
- Combination therapy Dabrafenib/Trametinib in BRAF V600 mutation-positive HGG
Abemaciclib for children and young adults with solid tumours (I3Y-MC-JPCS)
Entrectinib for children with solid tumours and brain tumours
- OSCAR - Treatment options for osteosarcoma
Selpercatinib, a RET-Inhibitor for children with solid tumours and brain tumours
Olaparib for children with solid tumors with HRR mutations
Erdafitinib in solid tumors with FGFR gene alterations (RAGNAR)